Bayer Ends Eliaxpixant Program Over Risks

Bayer said it will stop developing eliapixant, an investigational drug currently being evaluated in phase 2 studies for endometriosis, refractory chronic cough, overactive bladder and diabetic neuropathic pain.

Bayer said it made the decision after a “review of available data,” finding that the overall benefit “no longer outweighs the risk in these indications.”

The company gained access to eliapixant, a P2X3 receptor antagonist being investigated for treating hypersensitive nerve fibers-associated disorders, in a collaboration with Evotec. P2X3 receptors on peripheral sensory neurons play a role in the generation of chronic pain.

Eliapixant has not been approved for any indication in any country.